The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
about
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Recent advances in T-cell engineering for use in immunotherapyMismatch repair deficiency predicts response of solid tumors to PD-1 blockade.In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.Is autoimmunity the Achilles' heel of cancer immunotherapy?UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.The development of dendritic cell vaccine-based immunotherapies for glioblastoma.Immunosenescence and cancer.Targeting neoantigens to augment antitumour immunity.The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterationsCheckpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cellsIdentification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Informatics for cancer immunotherapy.The diverse functions of the PD1 inhibitory pathway.The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.Treating hematological malignancies with cell therapy: where are we now?Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial.Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.Strategies for Increasing Pancreatic Tumor Immunogenicity.Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.Immune oncology, immune responsiveness and the theory of everything.Mismatch repair-based stratification for immune checkpoint blockade therapy
P2860
Q27691330-EF70E585-10BA-4ACD-A12F-C0F247A47BD1Q28080312-AE8FAC5A-0203-477E-BD93-6C0A87B01652Q34557699-88FADFA8-67E9-48D8-8AAF-366BD789EB19Q37286552-B59E120F-F19B-43E0-A417-719F9B1FB61AQ37473978-056B338D-F86E-4082-AEB2-167850F9907DQ38687375-34A25792-5A48-44BE-A324-724AA276104CQ38708831-F9EAC63D-B5AA-40D8-93EB-FA21C250E3AAQ38990679-6F898F10-F4DE-4460-94B9-26B57EA75F1AQ39144853-1F1B7381-CC95-406C-BC03-82E4DABC63ABQ39149196-23DEF06F-65AC-45F6-9F26-1EA8FB81D05CQ39692283-CAF293A3-90B1-4D06-A918-D3019F521DD3Q41701367-6553DC09-2B8E-4806-869D-56B731E0A1EBQ47133741-019E108A-F697-4FDB-AD95-30D359AAAEE9Q47290509-84EEB104-EB68-46CE-9E55-8D1B2198ADE0Q47678849-947A3C39-D705-441D-BCEB-77868B00C228Q47970694-933D7AE4-D493-457A-AF81-6D9E71560218Q47984396-5BC7F5F1-7B79-4121-BA89-7C89E18D9648Q48640926-B0A304EA-B7EA-4258-A58C-C6E09106A55FQ49237244-6F6C571B-8A25-4D16-8980-DEF3D9F492D1Q50138585-26B6EEBA-385E-4BDD-9893-89CEC0695CD7Q52691832-F2FD187A-B5EE-4187-9A34-8460380B7BD8Q55232303-6A562551-ADB9-4AF9-B054-5E16F00ED4DFQ55321107-B9DE69F5-4CF0-47B1-A170-A8E66CC13E60Q55487467-D3420DF1-51A0-4004-9139-F9EA6159B005Q58790068-32C503D8-E96D-48B0-9ADD-B4D80B79F43E
P2860
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Role of Neoantigens in Nat ...... ed Immune Responses to Cancer.
@en
type
label
The Role of Neoantigens in Nat ...... ed Immune Responses to Cancer.
@en
prefLabel
The Role of Neoantigens in Nat ...... ed Immune Responses to Cancer.
@en
P2093
P2860
P1476
The Role of Neoantigens in Nat ...... ed Immune Responses to Cancer.
@en
P2093
Jeffrey P Ward
Matthew M Gubin
Robert D Schreiber
P2860
P356
10.1016/BS.AI.2016.01.001
P577
2016-02-10T00:00:00Z